多发性骨髓瘤血源性髓外复发:127例多中心回顾性研究
该多中心回顾性研究纳入127例接受新型药物治疗后出现血源性髓外复发(HEMM)的多发性骨髓瘤患者,评估其特征与结局。HEMM中位出现时间为32个月,中位生存仅6个月;IMiDs与更高总缓解率相关,未达≥VGPR是唯一显著影响总生存的不良因素。
要点
- HEMM中位出现时间为32个月,中位生存仅6个月,预后不良。
- IMiDs与更高ORR相关(HR 2.2,95%CI 1.02-4.7,P=.04)。
- 未达≥VGPR是唯一显著影响OS的不良因素(HR=9.87,95%CI 2.35-39,P=.001)。
核心结论
- HEMM在初诊后3年内发生,且与不良结局相关。
- IMiDs可能提供更高的缓解率,达到≥VGPR预示更长生存。
研究设计与样本
- 多中心回顾性研究,纳入2010-2018年间诊断为HEMM的连续多发性骨髓瘤患者127例。
- HEMM诊断依据影像学(87.3%)和/或活检(79%)。
主要发现
- 初诊时44%为ISS3期,57%有浆细胞瘤,30%有高危细胞遗传学。
- HEMM中位时间为32个月;多因素分析中ISS3和骨浆细胞瘤预测更短HEMM时间(P=.005和P=.008), upfront自体移植与更长HEMM时间相关(P=.002)。
- HEMM时32%无骨髓浆细胞增多,20%为非分泌型疾病,43%为轻链型疾病;52%有多个HEMM部位,常见软组织、皮肤(29%)和胸膜/肺(25%)。
- HEMM首次治疗包括蛋白酶体抑制剂(50%)、免疫调节剂(IMiDs)(39%)、单克隆抗体(10%)和化疗(53%);ORR为57%;IMiDs与更高ORR相关(HR 2.2,95%CI 1.02-4.7,P=.04)。
- HEMM后中位生存6个月(95%CI 4.8-7.2);多因素分析中未达≥VGPR是唯一显著影响更差OS的因素(HR=9.87,95%CI 2.35-39,P=.001)。
关键数值与推荐
- HEMM诊断依据影像学(87.3%)和/或活检(79%)。
- IMiDs与更高ORR相关(HR 2.2,95%CI 1.02-4.7,P=.04)。
- 未达≥VGPR是唯一显著影响更差OS的因素(HR=9.87,95%CI 2.35-39,P=.001)。
临床怎么用
- 对于多发性骨髓瘤患者,需关注HEMM的发生,其中位出现时间为32个月。
- HEMM治疗中IMiDs可能与更高缓解率相关,达到≥VGPR与更长生存相关。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The current study assesses the characteristics and outcomes of multiple myeloma (MM) patients, treated with novel agents for hematogenous extramedullary (HEMM) relapse. Consecutive patients diagnosed with HEMM between 2010-2018 were included. Patients' characteristics at diagnosis and at HEMM presentation, response to treatment, survival and factors predicting survival were recorded and analyzed. A group of 127 patients, all diagnosed with HEMM by imaging (87.3%) and/or biopsy (79%), were included. Of those, 44% were initially diagnosed with ISS3, 57% presented with plasmacytomas, and 30% had high-risk cytogenetics. Median time to HEMM was 32 months. In multivariate analysis, ISS3 and bone plasmacytoma predicted shorter time to HEMM (P = .005 and P = .008, respectively). Upfront autograft was associated with longer time to HEMM (P = .002). At HEMM, 32% of patients had no BM plasmacytosis, 20% had non-secretory disease and 43% had light-chain disease. Multiple HEMM sites were reported in 52% of patients, mostly involving soft tissue, skin (29%), and pleura/lung (25%). First treatment for HEMM included proteasome inhibitors (50%), immunomodulatory drugs (IMiDs) (39%), monoclonal antibodies (10%), and chemotherapy (53%). Overall response rate (ORR) was 57%. IMiDs were associated with higher ORR (HR 2.2, 95% CI 1.02-4.7, P = .04). Median survival from HEMM was 6 months (CI 95% 4.8-7.2). Failure to achieve ≥VGPR was the only significant factor for worse OS in multivariate analyses (HR = 9.87, CI 95% 2.35 - 39, P = .001). In conclusion, HEMM occurs within 3 years of initial myeloma diagnosis and is associated with dismal outcome. The IMiDs might provide a higher response rate, and achievement of ≥VGPR predicts longer survival.
引用
- Avivi I, Cohen YC, Suska A, et al. Hematogenous extramedullary relapse in multiple myeloma - a multicenter retrospective study in 127 patients. Am J Hematol. 2019. PMID: 31334859. doi:10.1002/ajh.25579
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。